Double-blind, randomised, placebo-controlled trial of allergen-specific immunotherapy with major allergen Alt a 1

It is the first phase III clinical trial conducted with only one protein, Alt a 1, for the treatment of allergies. Significant clinical improvement has been achieved after one year of treatment with a high safety profile.

Source: Journal of Allergy and Clinical Immunology - March 13, 2019 Category: Allergy & Immunology Authors: Ana Isabel Tabar, Luis Prieto, Pilar Alba, Antonio Nieto, Mercedes Rodr íguez, Miguel Torrecillas, Beatriz Huertas, Elisa Gómez, Francisco Javier Fernández, Miguel Blanca, David Rodríguez, Ricardo Palacios Source Type: research